Clinical trial NCT02270476: Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
Official title: Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cystic Fibrosis Lung Disease
Keywords: Cystic Fibrosis
Infant
Toddler
Children
Newborn screening
Lead sponsor: Heidelberg University
Sponsor class: OTHER
Collaborators: name: German Center for Lung Research
First posted: 2014-10-21
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with CF diagnosed in the first 4 months of life (corrected age of 4 months in preterms) not before January 1st, 2006 build up the early diagnosed (ED) group. Early identification can be achieved by newborn screening, clinical diagnosis (e.g. patients with meconium ileus), due to positive family history or prenatal diagnosis. Patients with CF diagnosed after the first 4 months of life and after January 1st, 2006, are included as a comparison group with clinically diagnosed patients (late diagnosed, LD). Both groups (ED and LD) are investigated after the same investigational plan with all investigations that are part of the annual check-up and additional, study-related monthly telephone interviews on bronchopulmonary symptoms, quarterly assessment of QoL and voluntarily yearly bronchoscopy with broncho-alveolar lavage.

Brief summary: The purpose of this study is to further characterize early CF lung disease in newborns, infants and toddlers with cystic fibrosis (CF).

Detailed description: Cystic fibrosis (CF) is the most common lethal genetic multisystem disease in Germany. Although life expectancy increased over the last decades, most of the CF patients die in young adulthood due to chronic CF lung disease with respiratory failure. CF lung disease is caused by a disturbed transport of salt and water by airway epithelia and dehydration of airway surfaces as a result of the underlying genetic defect in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gen. Up to now, no causal therapies for the majority of patients with CF are available. Little is known about onset and natural course as well as influencing factors of CF lung disease. Therefore, the first aim of this prospective, multicenter, uncontrolled, non-randomized, explorative longitudinal study is characterization of the onset and early course of CF lung disease. For this reason we will primarily include patients diagnosed by CF newborn screening (CF-NBS) or for any other reason in the first four months of life (early diagnosed, ED). In a second step we will compare data from these patients to those diagnosed clinically later in life (late diagnosed, LD). This will allow us to investigate the effect of early diagnosis and start of therapy. Starting at diagnosis, we will use data from annual routine check-ups (imaging like chest MRI, pulmonary function tests, microbiology from swabs and sputum, laboratory values, anthropometry) as well as data from a facultative, study-related bronchoscopy with lavage (microbiology, inflammation and immunology) for correlation with the course of CF lung disease (generation of hypotheses). Further study-related investigations are monthly telephone interviews on bronchopulmonary symptoms by a study nurse on the basis of a questionnaire and quarterly assessment of health-related quality of life on the basis of a validated questionnaire.

We expect to gain a deeper insight into onset and early course of CF lung disease from the results of this study. So far, there is no trial that investigated the different aspects of CF lung disease (function, morphology, infectiology, inflammation) complementary in a longitudinal setting. We assume that knowledge on the natural history of CF lung disease in the vulnerable phase of early childhood has a great impact on the future development of new therapies (from symptomatic to causal). This shall lead to a further improvement in life expectancy and quality of life of patients with CF.

Eligibility criteria: Inclusion Criteria:

1. Newly diagnosed patients with Cystic Fibrosis (CF). Diagnosis of CF: at least one of the following three international accepted criteria is fulfilled: i) sweat chloride ≥ 60mEq/L and/or ii) 2 CF-causing mutations in the CFTR gene and/or iii) changes typical for CF in the transepithelial potential difference in nasal or rectal epithelium.
2. Age and mode of diagnosis:

   * Early diagnosed (ED): Initial diagnosis following CF-NBS or for other reasons in the first 4 months of life (in preterms corrected age of 4 months) after January 1st, 2006. Other reasons could be prenatal diagnostics, meconium ileus or positive family history.
   * Late diagnosed (LD): Diagnosed after the fourth month of life due to clinical symptoms; initial diagnosis after January 1st, 2006.

Exclusion Criteria:

All patients are excluded who themselves or whose parents do not want to participate or that withdraw from the study; or those in whom the diagnosis of CF is unsure.

Further exclusion criteria are:

1. Preterms \<30th week of gestation
2. Longer period of mechanical ventilation in first 3 months of life
3. A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol
4. Previous major surgery except for meconium ileus or atresia of the intestine
5. Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to CF
6. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator
7. Chronic lung disease other than CF (e.g. bronchopulmonary dysplasia)
8. History of adverse reaction to medication for sedation or known claustrophobia

Criteria, which lead to a displacement of the procedures in sedation until the child has recovered: - Clinically significant upper airway obstruction as determined by investigator (e.g.

severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea)

- Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy

Primary outcomes:
measure: Proportion with morphological and/or perfusion changes due to CF lung disease after chest MRI score in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Proportion of patients with impairments in pulmonary function tests (e.g. multiple breath washout (MBW)) in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
Secondary outcomes:
measure: Rate of protocol-defined pulmonary exacerbations in both groups (ED vs. LD) that are necessitating an antibiotic therapy orally, intravenously or per inhalation
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Spontaneous development of infection or spectrum of pathogens, respectively, in throat and nose swabs as well as other airway secretions from routine diagnostics and if applicable bronchoalveolar lavage fluid (BALF)
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: From the patients in whom PsA or other CF pathogens could not be isolated at the beginning of their participation, comparison of the portion of patients with a positive culture during participation in both groups (ED and LD)
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Time to first detection of a CF pathogen in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Time to first pulmonary exacerbation in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Portion of patients with increased biochemical inflammatory markers in both groups and magnitude of elevation
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Frequency of symptoms from monthly telephone interviews in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Health-related quality of life in both groups quarterly via Cystic Fibrosis Questionnaire (CFQ)
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Development of body weight, body height, ideal weight-for-height (IWFH), Body-Mass-Index (BMI), respiratory rate and oxygen saturation at room air in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Proportion with morphological changes due to CF lung disease after modified Chrispin-Norman Score for assessment of chest X-ray in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Magnitude and severity of alterations typical for CF by assessment with chest MRI and X-ray score in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
measure: Magnitude of impairment of pulmonary function test in both groups
timeFrame: At age of 1, 2, 3, ...., 10 years of age
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: University Children's Hospital Heidelberg, Cystic Fibrosis Centre
state: Baden-Württemberg
city: Gießen
country: Germany
facility: University Hospital Gießen and Marburg GmbH
state: Hessen
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
state: Niedersachsen
city: Lübeck
country: Germany
facility: University Children's Hospital Schleswig-Holstein
state: Schleswig-Holstein
Study officials:
affiliation: University Hospital Heidelberg
name: Marcus A Mall, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Stahl M, Steinke E, Graeber SY, Joachim C, Seitz C, Kauczor HU, Eichinger M, Hammerling S, Sommerburg O, Wielputz MO, Mall MA. Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2021 Oct 15;204(8):943-953. doi: 10.1164/rccm.202102-0278OC.
citation: Stahl M, Wielputz MO, Graeber SY, Joachim C, Sommerburg O, Kauczor HU, Puderbach M, Eichinger M, Mall MA. Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2017 Feb 1;195(3):349-359. doi: 10.1164/rccm.201604-0893OC.